{"entity":{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","aka":["BEACON-1"],"tldr":"A phase 1/2 trial of AVZO-103 in bladder & urothelial cancer, run by Avenzo Therapeutics, Inc., now recruiting.","summary":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001). ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 355 participants. Primary completion is estimated at 2030-03. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AVZO-103, Combination Agent. Registered primary measures: Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1); Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1); Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07193511","url":"https://clinicaltrials.gov/study/NCT07193511"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":["avenzo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 355 participants. Primary completion is estimated at 2030-03. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07193511","phase":"1/2","setting":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","sponsor":"Avenzo Therapeutics, Inc.","participation":[{"nct":"NCT07193511","source":"https://clinicaltrials.gov/study/NCT07193511","fetchedAt":"2026-10-07T16:55:32.313Z","studySha256":"629c358e35ff229f7e92a1ea920663be1fdb6fb7f6e0040262b4ef8388041fd9","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-05","leadSponsor":"Avenzo Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":355,"enrolmentType":"ESTIMATED","siteCount":15,"recruitingSiteCount":15,"countries":["United States"]}],"started":"2025-10-02","startedType":"actual","enrolled":355,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07193511/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/"}],"drug":[{"id":"avzo-103","kind":"drug","name":"AVZO-103","route":"/drugs/avzo-103/"}]}}